Compare United States Brent Oil Fund LP (BNO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Novo Nordisk A/S — how do they compare? United States Brent Oil Fund LP trades at $50.51, while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while United States Brent Oil Fund LP pays none, and United States Brent Oil Fund LP is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| BNO | NVO | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $63.98 |
52-Week Low | $27.20 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO, tracking Brent crude oil futures, trades at $50.73, up 1.24% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights supply disruptions from the Strait of Hormuz standoff and OPEC's lowered demand forecasts, creating volatility. The stock lacks traditional financial ratios as it is an ETF, with performance tied directly to oil price movements and geopolitical developments.
Outlook hinges on oil market dynamics, with upside from sustained supply risks but downside from demand weakness. Risks include Middle East tensions and inventory builds. Analysts monitor EIA data and OPEC actions for direction, with current sentiment mixed amid headline-driven price swings.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
